scout
|Articles|August 24, 2009

Oncology NEWS International

  • Oncology NEWS International Vol 18 No 8
  • Volume 18
  • Issue 8

Yaupon locks up phase II Clearazide trial

Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.

Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.

The randomized study, slated for completion in 2010, has enrolled 260 patients from 13 cancer centers. Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.


Latest CME